血清胸苷激酶水平变化在非霍奇金淋巴瘤化疗过程的临床意义  

Changes of serum TK1 level during chemotherapy of patients with non-Hodgkin's lymphoma and its significance

作　　者：潘竹林[1] 季兴英[2] 石延敏[1] 

机构地区：[1]解放军第85医院血液科,上海200052 [2]海军第411医院血液科,上海200081

出　　处：《第二军医大学学报》2008年第11期1384-1385,共2页Academic Journal of Second Military Medical University

摘　　要：目的:探讨血清胸苷激酶(TK1)水平变化在非霍奇金淋巴瘤化疗过程的临床意义。方法:采用增强化学发光法检测37例非霍奇金淋巴瘤患者在化疗前、化疗结束1d、化疗结束后4周的血清TK1水平。结果:不同治疗期的血清TK1水平差异有统计学意义(P<0.01)。结论:血清TK1检测结果表明,在非霍奇金淋巴瘤患者化疗的临床疗效判断及复发预后中有重要的参考价值。Objective： To understand the significance of serum TK1 level change during chemotherapy of patients with non Hodgkin＇s lymphoma. Methods： The serum TK1 levels were detected in 37 patients with non-Hodgkin＇ s lymphoma by enhanced chemiluminecenee assay before chemotherapy and one day, four weeks after chemotherapy. Results： The changes of serum TK1 levels were significantly different at different stages of treatment （P〈0. 01）. Conclusion： Our findings indicate that serum TK1 change might be of great value in evaluating the treatment outcomes and predicting recurrence of patients with non-Hodgkin＇s lymphoma.

关 键 词：胸苷激酶1 非霍奇金淋巴瘤 药物疗法 

分 类 号：R733.41[医药卫生—肿瘤]